Biomarkers play an increasingly important role in drug discovery and molecular diagnostic programs. They can be detected either in diseased organs or in body fluids such as urine and blood. Some biomarker panels are already being utilized in preclinical research, for example in studies to demonstrate the effectiveness of an active ingredient (“proof of concept studies”) in animals, but also in phase I studies on humans.
Biomarkers are also relevant in terms of their diagnostic and prognostic value and are already being used to monitor the course of therapy. In later clinical studies (phase II and phase III studies), biomarkers are often referred to as surrogate endpoints.
HTCR-Servicers supports biomarker discovery and validation programs by providing bio-samples tissues (normal/diseased) and blood samples from patients (retrospectively / prospectively collected). The procurement of cohorts can be associated with clinical annotations including medication history and clinical outcome data.
For a list of available patient cohorts and disease indications please refer to our tissue portfolio in Custom Tissue Procurement and contact us for your specific request.